About Covance (NYSE:CVD)
Covance Inc. is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services. The early development services include lead optimization services, preclinical services and clinical pharmacology services. The late-stage development services include central laboratory, Phase II-IV clinical development, and market access services.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NYSE:CVD
- CUSIP: 22281610
- Web: www.covance.com
- 50 Day Moving Avg: $97.00
- 200 Day Moving Avg: $82.00
- 52 Week Range: $58.00 - $107.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 21.20
- P/E Growth: 0
- Net Margins: 7.70%
- Return on Equity: 12.64%
- Return on Assets: 8.17%
- Average Volume: 187,762 shs.
Frequently Asked Questions for Covance (NYSE:CVD)
What is Covance's stock symbol?
Covance trades on the New York Stock Exchange (NYSE) under the ticker symbol "CVD."
How were Covance's earnings last quarter?
Covance Inc. (NYSE:CVD) announced its quarterly earnings results on Wednesday, February, 4th. The company reported $0.97 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.97. The business had revenue of $634 million for the quarter, compared to analyst estimates of $631.30 million. Covance had a return on equity of 12.64% and a net margin of 7.70%. View Covance's Earnings History.
Who are some of Covance's key competitors?
Some companies that are related to Covance include Incyte Corporation (INCY), Quintiles Transitional Holdings (Q), Alnylam Pharmaceuticals (ALNY), Seattle Genetics (SGEN), Ionis Pharmaceuticals (IONS), Alkermes PLC (ALKS), Qiagen N.V. (QGEN), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), Galapagos NV (GLPG), Bio-Techne Corp (TECH), Puma Biotechnology (PBYI), PAREXEL International Corporation (PRXL), ACADIA Pharmaceuticals (ACAD) and FibroGen (FGEN).
How do I buy Covance stock?
Shares of Covance can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Covance's stock price today?
MarketBeat Community Rating for Covance (NYSE CVD)MarketBeat's community ratings are surveys of what our community members think about Covance and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Covance stock can currently be purchased for approximately $106.00.
Consensus Ratings for Covance (NYSE:CVD) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Covance (NYSE:CVD)
Analysts' Ratings History for Covance (NYSE:CVD)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Covance (NYSE:CVD)Earnings History by Quarter for Covance (NYSE CVD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/4/2015||Q414||$0.97||$0.97||$631.30 million||$634.00 million||View||N/A|
|11/3/2014||Q314||$0.98||$0.98||$651.00 million||$627.00 million||View||N/A|
|7/29/2014||Q214||$0.93||$0.95||$639.80 million||$687.10 million||View||N/A|
|5/1/2014||Q114||$0.90||$0.90||$632.01 million||$620.10 million||View||N/A|
|2/4/2014||Q413||$0.84||$0.87||$613.80 million||$623.00 million||View||N/A|
|7/30/2013||Q2 2013||$0.77||$0.78||$586.12 million||$644.00 million||View||N/A|
|5/1/2013||Q1 2013||$0.72||$0.75||$569.34 million||$580.20 million||View||N/A|
|1/24/2013||Q4 2012||$0.71||$0.73||$548.84 million||$562.20 million||View||N/A|
|11/5/2012||Q312||$0.67||$0.72||$546.52 million||$597.66 million||View||N/A|
Earnings Estimates for Covance (NYSE:CVD)
Current Year EPS Consensus Estimate: $4 EPS
Next Year EPS Consensus Estimate: $5 EPS
Dividend History for Covance (NYSE:CVD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Covance (NYSE:CVD)Insider Trades by Quarter for Covance (NYSE:CVD)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/22/2014||Brian H Nutt||Insider||Sell||1,127||$103.51||$116,655.77|| |
|12/18/2014||Joseph L Herring||CEO||Sell||32,692||$103.02||$3,367,929.84|| |
|12/10/2014||John E Watson||VP||Sell||15,200||$102.94||$1,564,688.00|| |
|9/9/2014||Joseph L Herring||CEO||Sell||32,200||$85.13||$2,741,186.00|| |
|2/20/2014||James Lovett||VP||Sell||14,955||$102.47||$1,532,438.85|| |
|2/10/2014||Brian Nutt||Insider||Sell||1,808||$100.12||$181,016.96|| |
|2/10/2014||Richard Cimino||EVP||Sell||13,000||$99.10||$1,288,300.00|| |
|2/10/2014||Sandra Helton||Director||Sell||2,800||$99.03||$277,284.00|| |
|9/20/2013||Richard Cimino||EVP||Sell||16,000||$84.86||$1,357,760.00|| |
|9/5/2013||Sandra L Helton||Director||Sell||3,000||$81.92||$245,760.00|| |
|9/5/2013||William E Klitgaard||VP||Sell||25,323||$81.44||$2,062,305.12|| |
|8/21/2013||Deborah Keller||EVP||Sell||15,900||$83.12||$1,321,608.00|| |
|8/16/2013||Robert Barchi||Director||Sell||13,667||$82.78||$1,131,354.26|| |
|8/2/2013||Gary Costley||Director||Sell||7,467||$82.77||$618,043.59|| |
|8/2/2013||Joseph Herring||CEO||Sell||100,000||$82.54||$8,254,000.00|| |
|6/27/2013||Joseph L Herring||CEO||Sell||13,259||$77.00||$1,020,943.00|| |
|6/19/2013||Joseph L Herring||CEO||Sell||22,391||$78.03||$1,747,169.73|| |
|5/15/2013||James W Lovett||VP||Sell||10,259||$77.00||$789,943.00|| |
Headline Trends for Covance (NYSE:CVD)
Latest Headlines for Covance (NYSE:CVD)
Loading headlines, please wait.
Covance (CVD) Chart for Monday, October, 23, 2017